November 1, 2007
Seaport World Trade Center
Boston, Massachusetts
The Primer has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of the Clinical Immunology Society and the International Society for Biological Therapy of Cancer. The Clinical Immunology Society is accredited by the ACCME to provide continuing medical education for physicians.
The Clinical Immunology Society designates this educational activity for a maximum of 6.75 AMA PRA Category 1 Credits. Physicians should claim credit commensurate with the extent of their participation in the activity.
The target audience for the Primer is basic and clinical investigators from academic, regulatory, and biopharmaceutical venues. The audience includes clinicians, researchers, students, post-doctoral fellows, and allied health professionals.
Attendees will learn about central concepts and recent advances in the field of biological therapy, including cancer vaccines, vaccine adjuvants, host-tumor interactions, the role of "danger" signals in integrating innate and adaptive immunity, T cell therapy, angiogenesis, antibody therapy, and cytokines.
Email correspondence will be sent to all attendees at the conclusion of this program with specific instructions to claim a CME certificate.
Click here to claim your CME credits.